Clinical trials: completed, in Papua New Guinea
Yaws, Cutaneous Ulcer
Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)
The goal of this clinical trial is to test the non inferiority of linezolid compared with azithromycin as a treatment for yaws .
- Trial name
- Trep-AByaws (NCT05764876)
- Testing
- Linezolid Oral Tablet, Azithromycin Oral Tablet
- Where
- Papua New Guinea
- Volunteers
- 383 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Plasmodium Falciparum Malaria, Pregnancy Malaria
Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea
Malaria during pregnancy remains an important public health issue in endemic countries. Most cases of malaria in pregnant women are asymptomatic, and can contribute to adverse outcomes, such as maternal and neonatal anaemia as…
- Conditions
- Plasmodium Falciparum Malaria, Pregnancy Malaria, Diagnoses Disease
- Trial name
- NCT03462615
- Testing
- HS-RDT
- Where
- Papua New Guinea
- Volunteers
- 930 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Vivax Malaria, G6PD Deficiency
Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea
Significant gains have been made in reducing the overall burden of malaria worldwide, however these have been far greater for Plasmodium falciparum than P. vivax. P.
- Trial name
- SCOPE (NCT05874271)
- Testing
- Revised case management package
- Where
- 4 sites in Papua New Guinea
- Volunteers
- 794 people
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Cutaneous Ulcer Disease, Skin Sores
Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG
Small cutaneous ulcers are common in Papua New Guinea but are normally left untreated due to lack of easy access to basic medicines.
- Trial name
- UP2024 (NCT06690814)
- Testing
- Ficus septica exudate (antiseptic plant exudates), Pterocarpus indicus exudate, Curcuma longa aqueous extract
- Where
- Papua New Guinea
- Volunteers
- 370 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis
East New Britain Province Monitoring & Evaluation
While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a public health problem by 2020…
- Conditions
- Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis, Acceptability of Mass Drug Administration for Lymphatic Filariasis
- Trial name
- ENBP M&E (NCT04124250)
- Testing
- Observational
- Where
- Papua New Guinea
- Volunteers
- 12,930 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Newborn Vaccine Immunogenicity
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
Infection is the most common cause of death in early life, especially for newborns and can be reduced by immunization but insufficient knowledge of how vaccines protect the very young limits their optimal use.
- Trial name
- EPIC-HIPC (NCT03246230)
- Testing
- Hepatitis B vaccine (HBV), Bacillus Calmette-Guérin (BCG)
- Where
- 2 sites in Papua New Guinea, The Gambia
- Volunteers
- 911 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Iodine Deficiency
Estimating Usual Iodine Intake From Spot Urinary Iodine Concentrations
The overall objective of this study is to develop a reliable method to obtain habitual iodine intakes from spot urinary iodine concentration (UIC) and to assess the prevalence of inadequate iodine intake in school-age children…
- Trial name
- ITURN (NCT03602404)
- Where
- 2 sites in Papua New Guinea, Russia
- Volunteers
- 1,592 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
Yaws
Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication
The current principle of yaws eradication (the Morges strategy) is based on single round mass drug administration (MDA) of azithromycin (AZI) called total community treatment (TCT) followed by targeted treatment of active cases…
- Trial name
- NCT03490123
- Testing
- R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin
- Where
- Papua New Guinea
- Volunteers
- 56,000 people, healthy volunteers welcome
- Sponsor
- Lihir Medical Centre
Lymphatic Filariases
Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis
This study will assess the impact of 2-drug (DA) or 3-drug (IDA) regimens on lymphatic filariasis infection parameters in communities.
- Trial name
- NCT03352206
- Testing
- 2 drug dose - DA, 3 drug dose - IDA
- Where
- 5 sites in Fiji, Haiti and 3 more
- Volunteers
- 20,092 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphatic Filariasis
Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
The DOLF Triple Drug Therapy for Lymphatic Filariasis study will determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB…
- Trial name
- NCT02899936
- Testing
- 3 drug dose - IDA, 2 drug dose - DA
- Where
- 4 sites in Haiti, India and 2 more
- Volunteers
- 23,789 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Yaws; Cutaneous, Cutaneous Ulcer
An Accessible Low-cost Plant Treatment for Cutaneous Ulcers
In a search for accessible treatment options, plant medicines used by different communities in Papua New Guinea have been tested to identify the sap of the tree, Ficus septica, as a promising antibacterial agent in vitro.
- Conditions
- Yaws; Cutaneous, Cutaneous Ulcer, Yaws
- Trial name
- NCT04453124
- Testing
- Topical antiseptic treatment
- Where
- 2 sites in Papua New Guinea
- Volunteers
- 150 people
- Sponsor
- Oriol Mitja
Pneumococcal Infections
PCV13 in Non-pregnant Papua New Guinean Women
This is an observational study to determine the reactogenicity and immunogenicity of pneumococcal conjugate vaccine in non-pregnant women of reproductive age in Papua New Guinea.
- Trial name
- NCT04183322
- Testing
- 13-valent pneumococcal conjugate vaccine
- Where
- Papua New Guinea
- Volunteers
- 50 people
- Sponsor
- Telethon Kids Institute
Lymphatic Filariasis
Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
The standard regimen for elimination of lymphatic filariasis (LF) in PNG is annual administration of two drugs at the same time.
- Trial name
- MDA (NCT03268252)
- Where
- Papua New Guinea
- Volunteers
- 3,200 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Lymphatic Filariasis, Yaws
PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
This is a Pharmacokinetic and Pharmacodynamic study evaluating the safety of co-administering Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination treatment for LF.
- Conditions
- Lymphatic Filariasis, Yaws, Trauma
- Trial name
- NCT03664063
- Testing
- Azithromycin, Albendazole, Ivermectin
- Where
- Papua New Guinea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Lihir Medical Centre
Trachoma, Yaws
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
This is a cluster randomised trial evaluating the safety of co-administering Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination treatment for LF.
- Conditions
- Trachoma, Yaws, Lymphatic Filariases, Scabies
- Trial name
- NCT03676140
- Testing
- Albendazole on Day 1, Ivermectin on Day 1, Diethylcarbamazine on day 1
- Where
- Papua New Guinea
- Volunteers
- 20,000 people
- Sponsor
- Lihir Medical Centre
Yaws
Comparison of Two Different Doses of Azithromycin for Treatment of Yaws
The study will be a single blinded, randomized, controlled open label non-inferiority phase III, trial with two parallel groups, conducted in Ghana and Papua New Guinea (PNG).
- Trial name
- NCT02344628
- Testing
- Azithromycin
- Where
- 7 sites in Ghana, Papua New Guinea and 1 more
- Volunteers
- 583 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Lymphatic Filariasis
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
This study will determine if a combination of 3 drugs used to treat the infection that cause lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in killing or sterilizing the adult worms compared to…
- Trial name
- NCT01975441
- Testing
- Diethylcarbamazine, Albendazole, Ivermectin
- Where
- Papua New Guinea
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Yaws
Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea
The trial that the investigators are proposing is a pilot study to determine the effect of the new WHO-yaws eradication strategy in Lihir Island (population 18,000), Papua New Guinea.
- Trial name
- YESA-13 (NCT01955252)
- Testing
- Azithromycin
- Where
- Papua New Guinea
- Volunteers
- 16,000 people
- Sponsor
- Lihir Medical Centre
Malaria
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
Mass drug administration with antimalarial treatment is a tool that can potentially reduce or totally eliminate malaria parasite infections from a population.
- Trial name
- ECG-Lihir (NCT02605720)
- Testing
- Dihydroartemisinin-piperaquine
- Where
- Papua New Guinea
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Lihir Medical Centre
Yaws
Dual Point-of-care Test for the Diagnosis of Yaws
A dual POC immunoassay simultaneously detecting non-treponemal and treponemal antibodies was developed for the diagnosis of infections with T. pallidum.
- Trial name
- YARADI (NCT01841203)
- Where
- 2 sites in Papua New Guinea
- Volunteers
- 703 people
- Sponsor
- Oriol Mitja